August 9, 2007
ERBITUX
Analysis of:
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate
Analysis: Since erbitux fail to show significant improvement in colon cancer.
I am not sure erbitux will be effective in any orhter cancer except Head and neck
Analysis: Since erbitux fail to show significant improvement in colon cancer.
I am not sure erbitux will be effective in any orhter cancer except Head and neck
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Painkiller Risk Found for Heart Patients
www.nytimes.com
FDA Asks if Pain Pill Is Tamper-Proof
online.wsj.com
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months
www.pipelinereview.com
Hospitals See Drop in Paying Patients
www.nytimes.com
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
www.fiercebiotech.com
Will contact lens solutions cost more to ship and store?
November 13, 2008
Economy's impact on healthcare facilities
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
November 13, 2008
CVS Escalates the Generic Price War
November 13, 2008
A closer look
November 11, 2008

